Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Azidamfenicol→

Azidamfenicol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
13838-08-9
Molecular formula
C11H13N5O5
Molecular weight
295.25 g/mol
Drug class
Amphenicol antibacterialchloramphenicol-related protein-synthesis inhibitor
Mechanism of action
Binds the 50S ribosomal subunit and inhibits peptidyl transferase activity, impairing bacterial protein synthesis. Antibacterial spectrum and clinical role depend on the specific formulation and local susceptibility.
Indications / reported uses
  • Historical or regional treatment of susceptible bacterial infections with topical or ophthalmic formulations where authorised; current availability and use are jurisdiction-specific

Sources: NLM MeSH — Azidamfenicol · PubMed — Azidamfenicol antibacterial pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Azidamfenicol Environmental Risk Assessment (ERA) (the Azidamfenicol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.